Pages that link to "Q39979581"

The following pages link to Comparison of neuropathy-inducing effects of eribulin mesylate, paclitaxel, and ixabepilone in mice (Q39979581):

Displaying 40 items.

• Eribulin in Cancer Treatment (Q26799328) (← links)
• Eribulin in the management of inoperable soft-tissue sarcoma: patient selection and survival (Q28074125) (← links)
• Feasibility and Efficacy of Eribulin Mesilate in Korean Patients with Metastatic Breast Cancer: Korean Multi-center Phase IV Clinical Study Results (Q33584160) (← links)
• Neuropathy-inducing effects of eribulin mesylate versus paclitaxel in mice with preexisting neuropathy (Q33815594) (← links)
• Overview of neuropathy associated with taxanes for the treatment of metastatic breast cancer (Q34458581) (← links)
• Eribulin mesylate in the treatment of metastatic breast cancer (Q35699382) (← links)
• Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane (Q35721526) (← links)
• Polygamain, a new microtubule depolymerizing agent that occupies a unique pharmacophore in the colchicine site (Q35776779) (← links)
• Epothilones in epithelial ovarian, fallopian tube, or primary peritoneal cancer: a systematic review. (Q35997562) (← links)
• Paclitaxel causes degeneration of both central and peripheral axon branches of dorsal root ganglia in mice (Q36073032) (← links)
• Eribulin mesylate: mechanism of action of a unique microtubule-targeting agent (Q36742259) (← links)
• Sustained Accumulation of Microtubule-Binding Chemotherapy Drugs in the Peripheral Nervous System: Correlations with Time Course and Neurotoxic Severity (Q36963585) (← links)
• Eribulin mesylate versus ixabepilone in patients with metastatic breast cancer: a randomized Phase II study comparing the incidence of peripheral neuropathy. (Q37067999) (← links)
• Eribulin drug review (Q37654001) (← links)
• Eribulin monotherapy in patients aged 70 years and older with metastatic breast cancer (Q37698199) (← links)
• Electrophysiological, behavioral and histological characterization of paclitaxel, cisplatin, vincristine and bortezomib-induced neuropathy in C57Bl/6 mice (Q37734620) (← links)
• Eribulin (Q37902645) (← links)
• Eribulin: a novel cytotoxic chemotherapy agent (Q38012442) (← links)
• Clinical efficacy of eribulin mesylate for the treatment of metastatic soft tissue sarcoma (Q38688042) (← links)
• Efficacy and safety of eribulin in taxane-refractory patients in the 'real world'. (Q38741802) (← links)
• Anti-Microtubule Drugs (Q38837821) (← links)
• Pharmacological therapies for Liposarcoma (Q38991731) (← links)
• Eribulin in heavily pretreated metastatic breast cancer patients and clinical/biological feature correlations: impact on the practice (Q39040318) (← links)
• Pain in chemotherapy-induced peripheral neurotoxicity (Q39363713) (← links)
• Effects of eribulin, vincristine, paclitaxel and ixabepilone on fast axonal transport and kinesin-1 driven microtubule gliding: implications for chemotherapy-induced peripheral neuropathy (Q42112858) (← links)
• Susceptibility of different mouse strains to oxaliplatin peripheral neurotoxicity: Phenotypic and genotypic insights (Q42705208) (← links)
• The role of TLR4 in the paclitaxel effects on neuronal growth in vitro (Q43245268) (← links)
• Effects of Paclitaxel and Eribulin in Mouse Sciatic Nerve: A Microtubule-Based Rationale for the Differential Induction of Chemotherapy-Induced Peripheral Neuropathy (Q43909454) (← links)
• Peripheral neuropathy induced by microtubule-targeted chemotherapies: insights into acute injury and long-term recovery. (Q46235962) (← links)
• Microtubule-Targeting Agents Eribulin and Paclitaxel Differentially Affect Neuronal Cell Bodies in Chemotherapy-Induced Peripheral Neuropathy (Q46283475) (← links)
• 14th Annual Meeting of the Safety Pharmacology Society: threading through scientific sessions for originality and novelty (Q46743817) (← links)
• Pharmacological augmentation of nicotinamide phosphoribosyltransferase (NAMPT) protects against paclitaxel-induced peripheral neuropathy. (Q47151258) (← links)
• Insulin-like growth factor-1 attenuates apoptosis and protects neurochemical phenotypes of dorsal root ganglion neurons with paclitaxel-induced neurotoxicity in vitro (Q48833230) (← links)
• Activity of eribulin mesylate in patients with soft-tissue sarcoma: a phase 2 study in four independent histological subtypes. (Q53217895) (← links)
• Silencing A7-nAChR levels increases the sensitivity of gastric cancer cells to ixabepilone treatment. (Q53800820) (← links)
• Eribulin mesylate in breast cancer. (Q54694130) (← links)
• Chemotherapy-induced peripheral neuropathy in breast cancer patients treated with eribulin: interim data from a post-marketing observational study (Q57461650) (← links)
• Evaluation of Eribulin Combined with Irinotecan for Treatment of Pediatric Cancer Xenografts (Q90407359) (← links)
• Differential Morphological and Biochemical Recovery from Chemotherapy-Induced Peripheral Neuropathy Following Paclitaxel, Ixabepilone, or Eribulin Treatment in Mouse Sciatic Nerves (Q90554778) (← links)
• Chemotherapy-induced peripheral neuropathy: Identifying the research gaps and associated changes to clinical trial design (Q98383559) (← links)